RxDoctor Payments Data

Teah Doles-Johnson

Psychiatric/Mental Health · High Point, NCNPI 1982062758

Payments from drug & device makers

$2,951in general payments, 2019–2025

Across 95 payments — averaging $31.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$387
  • Tris Pharma Inc$377
  • Johnson & Johnson$369
  • Teva Pharmaceuticals USA, Inc.$287
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$287
  • Otsuka America Pharmaceutical, Inc.$225
  • plus $1K from 10 others

What the payments were for

  • Food & beverage$2,951100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,951 in reported general payments places this provider in the 85th percentile of 947 psychiatric/mental health providers in North Carolina.

See all psychiatric/mental health providers in North Carolina

Medicare billing

Part B allowed, 2024
$64,717
Medicare patients
123
Services billed
664

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl18$24,991
RexultiBrexpiprazole11$11,528
EliquisApixaban15$6,727
Breo ElliptaFluticasone/Vilanterol11$4,738
Atomoxetine Hcl27$3,983
Aripiprazole92$3,710
Clonazepam88$1,792
Lurasidone Hcl15$1,547
Duloxetine Hcl63$1,156
Quetiapine Fumarate43$538
Sertraline Hcl89$499
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine14$489
Doxepin Hcl34$484
Trazodone Hcl76$468
Buspirone Hcl53$467

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$387$24,99118 claims
Otsuka America Pharmaceutical, Inc.Rexulti$225$11,52811 claims
Almatica Pharma LLCSertraline Hcl$81$49989 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 947 psychiatric/mental health providers in North Carolina.

Other psychiatric/mental health in High Point

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →